期刊
CLINICAL INFECTIOUS DISEASES
卷 76, 期 3, 页码 E652-E660出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciac621
关键词
HIV; tenofovir alafenamide; switch; weight gain; metabolic events
This study investigated the metabolic effects of switching from TDF to TAF. The results showed an increase in weight, total cholesterol, and triglycerides after switching to TAF, with no observed increase in obesity or metabolic-related diseases.
In this multicenter prospective cohort study with propensity score matching, we found a weight gain of 0.5 kilograms at 144 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide, with no difference in the incidence of metabolic clinical events. Background Tenofovir alafenamide (TAF) has replaced tenofovir disoproxil fumarate (TDF) in many clinical settings. However, concerns remain about potential metabolic complications of TAF. We aimed to evaluate changes in weight, laboratory markers, and metabolic-related clinical events after replacing TDF with TAF. Methods Multicenter prospective cohort study in the Spanish CoRIS cohort. We included virologically suppressed adults with human immunodeficiency virus (HIV) receiving TDF for more than 12 months who either switched to TAF or maintained TDF, with no changes in the core agent. Participants were matched by propensity score. We fitted generalized equation models to assess changes in weight, blood lipids, and hepatic steatosis index, and to compare the incidence of diabetes, hypertension, and lipid-lowering drug use after 144 weeks. Results In total, 1446 participants were matched in each group. Median age was 38 years, 85% were male, mean weight at baseline was 73 kg. Participants who switched to TAF had a mean weight increase of +0.5 kg at 144 weeks over those who maintained TDF, with no difference in the occurrence of overweight or obesity. Individuals who switched to TAF had a significant increase in total cholesterol (+7.9 mg/dL) and triglycerides (+11.2 mg/dL), with no differences in the total cholesterol-high-density lipoprotein (HDL) ratio. However, no increased incidence of diabetes, hypertension, or lipid-lowering drug use was observed after the follow-up period. Conclusions Switching from TDF to TAF is associated with modest weight gain and increases in total cholesterol and triglycerides, without an impact on the incidence of obesity or metabolic-related clinical events, in this Spanish cohort with a majority White male population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据